You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for New Drug Application (NDA): 022145


✉ Email this page to a colleague

« Back to Dashboard


NDA 022145 describes ISENTRESS HD, which is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from nine suppliers. There are five patents protecting this drug. Additional details are available on the ISENTRESS HD profile page.

The generic ingredient in ISENTRESS HD is raltegravir potassium. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.
Summary for 022145
Tradename:ISENTRESS HD
Applicant:Msd Sub Merck
Ingredient:raltegravir potassium
Patents:6
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022145
Generic Entry Date for 022145*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022145
Mechanism of ActionHIV Integrase Inhibitors
Medical Subject Heading (MeSH) Categories for 022145
Suppliers and Packaging for NDA: 022145
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ISENTRESS raltegravir potassium TABLET;ORAL 022145 NDA Merck Sharp & Dohme LLC 0006-0227 0006-0227-61 60 TABLET, FILM COATED in 1 BOTTLE (0006-0227-61)
ISENTRESS raltegravir potassium TABLET;ORAL 022145 NDA Merck Sharp & Dohme LLC 0006-3080 0006-3080-01 60 TABLET, FILM COATED in 1 BOTTLE (0006-3080-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 400MG BASE
Approval Date:Oct 12, 2007TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Apr 3, 2024Product Flag?Substance Flag?Delist Request?
Patent:⤷  Try a TrialPatent Expiration:Sep 11, 2029Product Flag?Substance Flag?Delist Request?Y
Patent:⤷  Try a TrialPatent Expiration:Jun 2, 2030Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HIV INFECTION

Expired US Patents for NDA 022145

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.